**Table S2** ACR20 response over the 24-week double-blind period (non-responder imputation for early escape)

|  |  |  |  |
| --- | --- | --- | --- |
| **Time (weeks)** |  | **Abatacept (n=213)** | **Placebo (n=211)** |
| 2 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 37/213 (17.4)(12.3 to 22.5)5.1 (–1.5 to 11.8) | 26/211 (12.3)(7.9 to 16.8)N/A |
| 4 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 67/213 (31.5)(25.2 to 37.7)12.2 (4.2 to 20.2) | 41/211 (19.4)(14.1 to 24.8)N/A |
| 8 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 76/213 (35.7)(29.2 to 42.1)8.3 (–0.4 to 17.0) | 58/211 (27.5)(21.5 to 33.5)N/A |
| 12 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 81/213 (38.0)(31.5 to 44.5)9.2 (0.4 to 17.9) | 61/211 (28.9)(22.8 to 35.0)N/A |
| 16 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 87/213 (40.8)(34.2 to 47.4)13.8 (5.0 to 22.6) | 57/211 (27.0)(21.0 to 33.0)N/A |
| 20 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 80/213 (37.6)(31.1 to 44.1)14.3 (5.8 to 22.8) | 49/211 (23.2)(17.5 to 28.9)N/A |
| 24 | Number of patients, n/n (%)95% CIEstimate of difference (95% CI) | 84/213 (39.4)(32.9, 46.0)17.2 (8.7, 25.6) | 47/211 (22.3)(16.7, 27.9)N/A |

Early escape patients switching to open-label abatacept at week 16 were imputed as non-responders at weeks 20 and 24. At all time points, if there were missing data, patients were imputed as non-responders, unless data were missing between two time points at which the patient had a response, in which case response was imputed. ACR20, ≥20% improvement in American College of Rheumatology criteria; CI, confidence interval; N/A, not applicable.